New Strategies to Detect Cancers in Carriers of Mutations in RB1

CompletedOBSERVATIONAL
Enrollment

378

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
RetinoblastomaSecondary Primary Malignancies After Retinoblastoma
Interventions
OTHER

blood draw

"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."

Trial Locations (3)

Unknown

Institute Curie, Paris

University Hospital Essen (UHE), Essen

Amsterdam UMC, location VUmc, Amsterdam

All Listed Sponsors
collaborator

University Hospital, Essen

OTHER

collaborator

Institut Curie

OTHER

collaborator

Ligue contre le cancer, France

OTHER

lead

Amsterdam UMC, location VUmc

OTHER

NCT04164134 - New Strategies to Detect Cancers in Carriers of Mutations in RB1 | Biotech Hunter | Biotech Hunter